Related Experiment Video
Updated: Sep 25, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
COVID-19 mRNA Vaccine-Associated Myocarditis Presenting as STEMI in a 48-Year-Old Male
Mohammad Dlewati1, Kyeeun Park1, Saumya Rawat1
1Division of Internal Medicine, Memorial Healthcare System, Hollywood, Florida, USA.
Abstract:
Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations. Young adult and adolescent males < 30 years of age are the most commonly affected group, with decreased incidence with older age. This is a case of a 48-year-old male who presented with chest pain and EKG findings of STEMI shortly after receiving the second dose of the Moderna COVID-19 mRNA vaccine. Emergent left heart catheterization revealed normal coronaries. Subsequently, the patient had rapid resolution of his symptoms and improvement in serum markers. The exact etiology factors to this new and rare phenomenon are yet to be fully understood. This patient did have a history of previous viral myocarditis 7 years ago; however, it remains unclear if this could be a predisposing factor to the development of mRNA vaccine-associated myocarditis.
More Related Videos
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome I: Introduction
Myocarditis I: Introduction
Coronary Artery Disease III: Clinical Manifestations
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

